In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
- 3 February 2017
- journal article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 72 (5), 1373-1385
- https://doi.org/10.1093/jac/dkw593
Abstract
Diazabicyclooctanes (DBOs) inhibit class A, class C and some class D β-lactamases. A few also bind PBP2, conferring direct antibacterial activity and a β-lactamase-independent 'enhancer' effect, potentiating β-lactams targeting PBP3. We tested a novel DBO, zidebactam, combined with cefepime. CLSI agar dilution MICs were determined with cefepime/zidebactam in a chequerboard format. Bactericidal activity was also measured. Zidebactam MICs were ≤2 mg/L (mostly 0.12-0.5 mg/L) for most Escherichia coli , Klebsiella , Citrobacter and Enterobacter spp., but were >32 mg/L for Proteeae, most Serratia and a few E. coli , Klebsiella and Enterobacter/Citrobacter . The antibacterial activity of zidebactam dominated chequerboard studies for Enterobacteriaceae, but potentiation of cefepime was apparent for zidebactam-resistant isolates with class A and C enzymes, illustrating β-lactamase inhibition. Overall, cefepime/zidebactam inhibited almost all Enterobacteriaceae with AmpC, ESBL, K1, KPC and OXA-48-like β-lactamases at 1 + 1 mg/L and also 29 of 35 isolates with metallo-carbapenemases, including several resistant to zidebactam alone. Zidebactam MICs for 36 of 50 Pseudomonas aeruginosa were 4-16 mg/L, and the majority of AmpC, metallo-β-lactamase-producing and cystic fibrosis isolates were susceptible to cefepime/zidebactam at 8 + 8 mg/L. Zidebactam MICs for Acinetobacter baumannii and Stenotrophomonas maltophilia were >32 mg/L; potentiation of cefepime was frequent for S. maltophilia , but minimal for A. baumannii . Kill curve results largely supported MICs. Zidebactam represents a second triple-action DBO following RG6080, with lower MICs for Enterobacteriaceae and P. aeruginosa . Clinical evaluation of cefepime/zidebactam must critically evaluate the reliance that can be placed on this direct antibacterial activity and on the enhancer effect as well as β-lactamase inhibition.This publication has 17 references indexed in Scilit:
- Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal InfectionAntimicrobial Agents and Chemotherapy, 2016
- New insights into the regulatory pathways associated with the activation of the stringent response in bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595/RG6080Journal of Antimicrobial Chemotherapy, 2016
- Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamasesJournal of Antimicrobial Chemotherapy, 2015
- The β‐Lactams Strike Back: Ceftazidime‐AvibactamPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam ‘enhancer’Journal of Antimicrobial Chemotherapy, 2015
- New β‐lactam–β‐lactamase inhibitor combinations in clinical developmentAnnals of the New York Academy of Sciences, 2013
- In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniaeInternational Journal of Antimicrobial Agents, 2012
- Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolatesJournal of Antimicrobial Chemotherapy, 2010
- Identification of Acinetobacter baumannii by Detection of the bla OXA-51-like Carbapenemase Gene Intrinsic to This SpeciesJournal of Clinical Microbiology, 2006
- Mecillinam--an amidino penicillin which acts synergistically with other -lactam compoundsJournal of Antimicrobial Chemotherapy, 1977